MAP2K7 and melanoma: This promotes tumor progression, but, on the other hand, it represents a molecular target for therapy using MAPK inhibitors, such as BRAF and MEK inhibitors, which have shown response rates of up to 76% in patients with melanomas harboring BRAF mutations [5,6].